ViCentra, a European medical device company redefining insulin delivery for people with diabetes, announced the successful close of an upsized $85 million Series D financing led by new investor Innovation Industries, a leading European deeptech venture capital firm, with matching participation from existing investors Partners in Equity and Invest-NL, alongside continued support from EQT Life Sciences and Health Innovations. With this fresh funding, ViCentra will accelerate manufacturing scale-up, launch the next-generation Kaleido 2 patch pump in Europe, and prepare for U.S. market entry.

Kaleido is the smallest, lightest, and most precise insulin patch pump in its class, uniquely designed as a lifestyle product that is discreet, intuitive, and personalised. Designed to feel more like personal technology than a traditional medical device, Kaleido features premium materials, and users can select their own favourite aluminium shells from a range of ten preset colour options. Integrated with Diabeloop's self-learning automated insulin delivery algorithm and compatible with the Dexcom CGM sensor, Kaleido positions ViCentra at the forefront of next-generation diabetes care, helping reach many more users and improve the quality of life for people with diabetes. Strong initial commercial uptake of Kaleido in Germany, France, and the Netherlands has driven demand beyond initial expectations. This financing enables ViCentra to scale the business for rapid revenue acceleration.

"Kaleido is a true disruptor — small, discreet, featherlight, and beautifully designed. It empowers people with diabetes by offering a more personal and distinctive choice in both function and style. Built with empathy and precision, it honours those who live with diabetes every day. With this funding, we can now meet surging European demand and fast-track our entry into the U.S. market. This is a pivotal moment — for ViCentra, and for the community we serve," said Tom Arnold, Chief Executive Officer at ViCentra.